Jennison Associates
EGRX

Jennison Associates’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Jennison Associates’s Portfolio EGRX Stock Details EGRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2015
Q1 		– Sell
-688,843
Closed -$10.7M – 758
2014
Q4 		$10.7M Sell
688,843
-551
-0.1% -$7.04K 0.01% 481
2014
Q3 		$8.72M Buy
689,394
+613,558
+809% +$7.61M 0.01% 488
2014
Q2 		$1.09M Sell
75,836
-78,698
-51% -$897K ﹤0.01% 639
2014
Q1 		$1.97M Buy
+154,534
New +$2.1M ﹤0.01% 589

Other funds holding EGRX

PAI
ProQuest Associates IV Naples, Florida $53M AUM 3.35% 1-Year Est. Return
JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
JAM
JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return
GE
General Electric Evendale, Ohio $369M AUM 19.65% 1-Year Est. Return
CAM
Cormorant Asset Management Boston, Massachusetts $1.99B AUM 737.95% 1-Year Est. Return
PWAM
Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return
Allianz Asset Management
Allianz Asset Management Munich, Germany $95.4B AUM 38.74% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Jennison Associates's EGRX Position: Q1 2015 in Review

Jennison Associates sold out of Eagle Pharmaceuticals, Inc. (EGRX) in Q1 2015, closing a stake of 688,843 shares — an estimated $10.7M sold.

Jennison Associates first reported a position in EGRX in Q1 2014 and held it in 4 quarters. The position peaked at $10.7M in Q4 2014. 68 funds tracked by Wall St. Rank hold EGRX as of Q1 2015.

  • Jennison Associates reported no remaining Eagle Pharmaceuticals, Inc. position as of Q1 2015 after selling out during the quarter.
  • Jennison Associates sold 688,843 Eagle Pharmaceuticals, Inc. shares in Q1 2015, an estimated $10.7M.
  • Jennison Associates first reported a position in Eagle Pharmaceuticals, Inc. in Q1 2014 and held it in 4 quarters.
  • Jennison Associates's Eagle Pharmaceuticals, Inc. position peaked at $10.7M in Q4 2014.
  • 68 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q1 2015.

Based on Jennison Associates's 13F filing for Q1 2015, filed 4 May 2015.